Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

thinkemotive

- PMLiVE

WHO reveals ‘extensive’ worldwide overuse of antibiotics during COVID-19 pandemic

Findings from the report reveal factors that could have contributed to the spread of antimicrobial resistance

- PMLiVE

Is the gut microbiome the next frontier in medicine?

Research has long shown a strong connection between disease and the gut microbiome

- PMLiVE

The role of economic evaluation in US healthcare

Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US. They highlight important considerations for companies seeking...

Mtech Access – Powered by Petauri™

- PMLiVE

How to successfully manage change and enable digital transformation within pharma

Change is an essential aspect of any business, and learning to manage it effectively will be key for long-term success. Getting your team on board with change and digital transformation...

Graphite Digital

- PMLiVE

J&J’s Rybrevant combination recommended by CHMP to treat advanced lung cancer

The fully-human EGFR-MET bispecific antibody has been recommended as a first-line treatment option

- PMLiVE

AbbVie shares positive results for Rinvoq in head-to-head atopic dermatitis study

An estimated 10% of adults and 24.6% of adolescents are affected by the inflammatory skin condition

- PMLiVE

Pfizer’s one-time haemophilia B therapy Beqvez granted FDA approval

More than 38,000 people worldwide are currently affected by the rare genetic bleeding disorder

- PMLiVE

Strategising fast and slow

The best strategists understand their own thinking flaws

- PMLiVE

Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development

Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...

Research Partnership

regeneron headquarters

Regeneron and Mammoth announce gene editing partnership worth $370m per target

The companies will aim to develop CRISPR-based therapies for multiple tissues and cell types

- PMLiVE

BeiGene’s Tizveni receives EC approval to treat non-small cell lung cancer

Under the brand name Tevimbra, the company will combine the NSCLC indications with the second-line ESCC indication in late 2024

Biogen Idec building

Biogen’s tocilizumab biosimilar Tofidence recommended by CHMP to treat arthritis and COVID-19

The committee’s decision was supported by evidence demonstrating Tofidence’s similarity to Roche’s RoActemra

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links